BioCentury
ARTICLE | Finance

Reasons unknown

All parties mum as Chimerix CEO departs with stock up through Josh Hardy storm

April 14, 2014 7:00 AM UTC

The real story behind the unexpected departure of Chimerix Inc. President and CEO Kenneth Moch 29 days after the company extricated itself from a public relations crisis will probably never be known. It certainly wasn't because of the stock's performance.

The stock climbed steadily even as the embattled company tried to explain its initial refusal to grant compassionate access to brincidofovir for Josh Hardy, a pediatric cancer patient...